Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Forge Resources Intercepts 105 G/T Au in the Payoff Zone at Alotta Project, Yukon (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Arrivent Biopharma Inc AVBP

Healthcare Biotechnology
ArriVent BioPharma, Inc. is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. The Company is focused on maximizing the potential of its lead development candidate, firmonertinib, and advancing a pipeline of novel therapeutics, such as antibody... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:AVBP)

ArriVent BioPharma Reports Third Quarter 2025 Financial Results

GlobeNewswire 7 days ago

ArriVent Appoints Brent S. Rice as Chief Commercial Officer

GlobeNewswire September 22, 2025

Arrivent Presents the Final Analysis of Firmonertinib Monotherapy Data from Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2025 World Conference on Lung Cancer

GlobeNewswire September 9, 2025

ArriVent BioPharma Reports Second Quarter 2025 Financial Results

GlobeNewswire August 11, 2025

ArriVent's Topline Pivotal Phase 3 FURVENT Data for Firmonertinib in First-Line NSCLC EGFR Exon20 Insertion Mutations is Projected to be Early 2026

GlobeNewswire July 21, 2025

ArriVent Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded Warrants

GlobeNewswire July 1, 2025

ArriVent Announces Proposed $75 Million Public Offering of Common Stock and Pre-Funded Warrants

GlobeNewswire July 1, 2025

ArriVent Announces Positive Interim Firmonertinib Monotherapy Data From Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer and Plans to Advance into a Global Pivotal Study

GlobeNewswire June 23, 2025

ArriVent Announces Investor Event on Firmonertinib Path Forward for EGFR PACC Mutant NSCLC

GlobeNewswire June 20, 2025
View More News ››

Opinion & Analysis (NDAQ:AVBP)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:AVBP)

Be the first to post on this bullboard.

LaFleur Minerals Inc.

LaFleur Minerals Inc.

LaFleur Minerals Inc. is focused on the development of district-scale gold projects in the Abitibi Gold Belt near Val-d'Or ...
View More »